Effects of CYP2C19 genetic polymorphisms on the cure rates of H. pylori in patients treated with the proton pump inhibitors: An updated meta-analysis
Conclusion: Carriers of CYP2C19 loss-of-function variant alleles (IM and PM) exhibit a significantly greater cure rate of H. pylori than noncarriers (EM) regardless of other factors (84.7% vs. 79.2%). In addition, pantoprazole- and rabeprazole-based quadruple therapy for H. pylori treatment is less dependent on the CYP2C19 genotype and should be prioritized in Asian populations with H. pylori.
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
More News: Drugs & Pharmacology | Esomeprazole | Gastroenterology | Genetics | Helicobacter Pylori | Lansoprazole | Nexium | Omeprazole | Pantoprazole | Prevacid | Prilosec | Proton Pump Inhibitors PPIs | Protonix | Study